Zynerba Pharmaceuticals, Inc.’s net profit jumped 18.01% since last year same period to $-8.68Mn in the Q3 2022. On a quarterly growth basis, Zynerba Pharmaceuticals, Inc. has generated 11.94% jump in its net profits since last 3-months.
EPS Estimate Current Quarter
EPS Estimate Current Year
Zynerba Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.23 - a 0% jump from last quarter’s estimates.
Zynerba Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current year stand at -0.23.
Earning Per Share (EPS)
Return on Assets (ROA)
Return on Equity (ROE)
Zynerba Pharmaceuticals, Inc.’s earning per share (EPS) jumped 4% since last year same period to -0.24 in the Q2 2022. This indicates that the Zynerba Pharmaceuticals, Inc. has generated 4% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Zynerba Pharmaceuticals, Inc.’s return on assets (ROA) stands at -0.29.
The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Zynerba Pharmaceuticals, Inc.’s return on equity (ROE) stands at -0.55.
|Earnings Date||Estimated EPS||Reported EPS||Surprise %|
Zynerba Pharmaceuticals, Inc.
80 West Lancaster Avenue, Devon, PA, United States, 19333
Trading and brokerage services provided by
Banking and Remittance services provided by
Technology services provided by : Finzoomers Services Private Limited